TSE:4568Pharmaceuticals
Did EMA’s ENHERTU Validation and Leadership Changes Just Reframe Daiichi Sankyo’s (TSE:4568) Investment Narrative?
In February 2026, Daiichi Sankyo received European Medicines Agency validation to expand the indication of ENHERTU for HER2 positive early breast cancer, while also announcing leadership transitions including a new Global Head of R&D and upcoming changes to its board and audit members.
These developments, alongside a new AI-driven collaboration with BostonGene and ongoing litigation linked to past disputes, highlight how Daiichi Sankyo is reshaping its oncology innovation engine and...